Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 875,000 ordinary shares of 25 pence each.
- Purchase Date: August 2, 2011.
- Price Range: Highest price paid was 1,363.5 pence per share; lowest price paid was 1,345.5 pence per share.
- Treasury Holdings (Settled): 496,646,816 shares (8.86% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,596,816 shares (9.78% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,108,461,883 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program authorized at the Annual General Meeting on May 5, 2011. This transaction increased the company's treasury share holdings, thereby reducing the number of shares available for public trading and altering the denominator for voting rights calculations.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The text is limited to the factual reporting of the share transaction and the resulting capital structure.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (496,646,816 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights held in Treasury (9.78% including unsettled shares) for disclosure threshold calculations.
- Check the remaining authorized share buyback limit under the May 5, 2011 shareholder resolution.
- Review the settlement status of the 2,950,000 shares purchased but not yet settled at the time of filing.